Evidence map›Paper›PMID 40564879›Full record

ArticleDiagnostics (Basel, Switzerland)2025

18F-FDG PET/CT Impact on Malignant Melanoma Patients Undergoing Staging and Restaging: A Single-University-Center Experience in a Real-World Setting.

Silvija Lucic, Milena Spirovski, Borislava Nikolin, Dragana Stojanovic, Andrea Peter, Branislava Gajic, Vanja Cimbaljevic, Milos A Lucic

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Silvija LucicMedical Faculty, Oncology Institute of Vojvodina, University of Novi Sad, 21000 Novi Sad, Serbia.ORCID 0000-0002-3085-9831
Milena SpirovskiMedical Faculty, Oncology Institute of Vojvodina, University of Novi Sad, 21000 Novi Sad, Serbia.ORCID 0000-0002-5406-5841
Borislava NikolinMedical Faculty, Oncology Institute of Vojvodina, University of Novi Sad, 21000 Novi Sad, Serbia.
Dragana StojanovicOncology Institute of Vojvodina, 21000 Novi Sad, Serbia.
Andrea PeterMedical Faculty, Oncology Institute of Vojvodina, University of Novi Sad, 21000 Novi Sad, Serbia.
Branislava GajicMedical Faculty, University of Novi Sad, Clinic of Dermatovenereology Diseases, University Clinical Center of Vojvodina, 21000 Novi Sad, Serbia.
Vanja CimbaljevicOncology Institute of Vojvodina, 21000 Novi Sad, Serbia.
Milos A LucicMedical Faculty, Oncology Institute of Vojvodina, University of Novi Sad, 21000 Novi Sad, Serbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

18F-FDG PET/CTadvanced stagesearly stagesmalignant melanomasurvival

Identifiers

PMID40564879
PMCPMC12192031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.